Abstract Both in ankylosing spondylitis (ASP) and psoriatic arthritis (PsA), osteopenia is present in one-third of women and men, whereas osteoporosis mainly aVects men, even in their 30 s. Subclinical gut inXammation has been described in patients with AS or PsA. Joint involvement also occurs with other gastrointestinal diseases such as celiac disease. We tested the hypothesis, whether elevated serum levels of human anti-tissue-transglutaminase-IgA (htTG) are associated with changes in disease activity, vitamin D metabolism and bone mineral density (BMD) in patients with ASP and PsA. In a cross-sectional study, we evaluated both biochemical markers of bone turnover, BMD and htTG in 76 patients with ASP and 120 patients with PsA. A reduction of BMD in lumbar spine was determined both in ASP (42.7%) and in PsA (57.3%). Furthermore, a signiWcantly higher prevalence of htTG was detected only in ASP (14/76). ASP patients with negative htTG status have signiWcant higher 25-vitamin D3 levels. ASP patients with positive htTG status are younger. A positive htTG status entails the risk of a bad vitamin D supply, which should be considered in young patients since this constellation favors a reduction in bone density. The coincidence of ASP along with detection of htTG and clinically asymptomatic celiac disease as an accessory source of inXammation with a negative inXuence on the bone metabolism is also conceivable. Clinicians need to be aware of patients younger than 45 years with ASP, which have important implications for the correct treatment and vitamin D supplementation.
Introduction
Patients with both ankylosing spondylitis (ASP) and psoriatic arthritis (PsA) have local and systemic bone loss, and may be at an increased risk of suVering from bone fractures [1] [2] [3] [4] . Various factors such as treatment, hormone disorders, and decreased mobility or physical activity may contribute to development of osteopenia (osteoporosis in ASP and PSA) [5, 6] . A prospective study demonstrated a signiWcant loss of bone mass in early ASP with strong association with inXammation activity [7] . Celiac disease is a gluten sensitive enteropathy characterized by a wide spectrum of clinical manifestations, such as diarrhea, weight loss, anemia and herpetiform dermatitis. Most of these are related to malabsorption which may be limited to one or a few nutrients up to a complete malabsorptive syndrome. However, joint involvement, e.g. in sacroiliac joints has also been reported related to celiac disease [8] .
In this cross-sectional study we tested the hypothesis, weather positive human anti-tissue-transglutaminase-IgA (htTG) status is associated with alterations of vitamin D metabolism, osteoporosis/osteopenia, marker of inXammation, age of patients and HLA B 27 marker in a large and well-characterized cohort of patients with ASP or PsA.
Patients and methods
Seventy-six patients with ASP as deWned by the New York clinical criteria [9] (age range 19-58 years, mean 49.5 years, duration of disease 1-34 years, mean 19.3 years) and 116 patients with PsA as deWned by the classiWcation of psoriatic arthritis-CASPAR [10] (age range 22-61 years, mean 50.7 years, duration of disease 1-24 years, mean 17.1 years) were studied from March to November 2005. All the women were premenopausal with a physiologic sexual hormone status. A selective IgA-deWciency was excluded. Serum creatinine levels were normal in the entire study population. Criteria for exclusion were the presence of intestinal disease (terminal ileitis, ulcerative colitis), malnutrition, marasmus and drug intake known to aVect bone metabolism and the endocrine system. All study persons had been physically active twice a week during the preceding 12 months.
A medical history was obtained, 61 of 76 ASP patients and 107 of 116 PsA patients received intermittent nonsteroidal antirheumatic (NSAID) therapy in the previous 12 months. No patient was receiving glucocorticoid medication at the time of the study, only 7 patients had received such medication for a short time in the past (10 mg/day for 2-3 months during the disease duration) 32 PsA patients got a disease modifying medication at the time of the study (methotrexate 15 mg weekly in 24 cases and sulfasalazine in 8 cases).
Disease status in terms of disease activity, disease progression and prognosis, is diYcult to deWne in ASP and PsA. We used C-reactive protein (CRP), and the Westergren erythrocyte sedimentation rate (ESR).
Biochemical measurements
Blood examples were taken from all participants every morning at the same Wxed time. The collected serum samples were immediately stored in aliquots at ¡20°C in our serum bank before testing. Informed consent was obtained before blood sampling. The speciWc serum parameters of this study were calcitriol ("1,25 (OH)2 Vitamin D"-kit from Biermann Bad Nauheim, Germany); and calcifediol ("25 (OH) Vitamin D"-kit from Biermann Bad Nauheim, Germany)mun Diagnostik, Bensheim, Germany; competitive protein-binding assay). The Microtiter ELISA was intended for the determination of htTG antibodies in serum (Euroimmun Medizinische Labordiagnostik AG, Lübeck, Germany). (Expected value: htTG IgA serum cut oV >22 AU/ml positive, htTG IgA serum cut oV <16 AU/ml negative. Results between 16 and 22 AU/ml are in the gray range.) CRP (normal range <5 ng/l, immunonephelometry using Behring Nephelometer Systems, N Latex CRP mono, Behring Diagnostics, Marburg, Germany).
Assessment of bone mineral density
Bone mineral density (BMD) was measured at the lumbar spine and the left femoral neck by dual-energy X-ray absorptiometry (DEXA) using Prodigny Lunar (Milwaukee, WI, USA). The coeYcient of variation of repeated measurements was 0.9% for the lumbar spine and 1.6% for the femoral neck. Osteopenia (T score between ¡1.0 and ¡2.5) and osteoporosis (T score below ¡2.5) were deWned according to the criteria of the World Health Organization.
Statistical analysis
Results are presented by mean values and standard deviation. The following methods were applied for statistical analysis: a single factor variance analysis, the exact Fisher's test and the Mann-Whitney U test. The statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) for Windows [11] .
Results
In comparison with the PsA group (n = 4), ASP patients (n = 14) showed signiWcantly higher prevalence of htTG antibodies in serum. In 18 of 196 (9.81) patients we found positive htTG antibodies in serum (Table 1) . However, we found no statistically signiWcant association of positive htTG antibodies with the biochemical markers of inXammation: CRP and ESR ( Table 2 ). Measurement of BMD of ASP and PsA patients revealed osteoporose in 35/76 patients (42.7%) and 47/120 (57.3%). No associations were found between ASP or PsA and osteoporose (P value of exact Fisher's test P = 0.374) or positive htTG antibodies in ASP or PsA and osteoporose (P value of exact Fisher's test P = 0.130). Finally, in ASP patients HLA B 27 marker is not associated with positive htTG antibodies.
Serum levels of both 25 (OH) D3 and 1,25 (OH)2 D3 in the combined cohort of female and male patients with PsA were higher compared with the ASP group ( Table 3) . The 25 (OH) D3 levels in PsA were signiWcantly higher compared to those of ASP (P < 0.0005). Pooled cohort of patients both with ASP and PsA showed a statistically signiWcant negative correlation between CRP and 25(OH) D3 levels (P < 0.0005) ( Table 4 ). In patients with positive htTG antibodies the mean of 25 (OH) D3 levels was 17.4 ng/ml, whereas patients with negative htTG antibodies presented 41.5 ng/ml (Table 5 ). This diVerence was statistically signiWcant (P < 0.005). There was a similar trend in 1,25 (OH)2 Vitamin D3 but without any statistical signiWcance (P = 0.274).
Patients with positive htTG antibodies were younger than those of a negative antibody titer. More than 61% of the ASP and PsA patients with positive htTG antibodies were younger than 45 years (Table 6 ).
Discussion
The aim of our study was to Wnd unidentiWed or neglected cases of positive htTG antibodies by using serological screening in a large and well-characterized cohort of patients with ASP or PsA. In 14/76 ASP patients, positive htTG antibodies in serum were detected. In the consecutive endoscopy none of these patients presents the typical villous atrophy with crypt hyperplasia in small bowel biopsy specimen, which conWrmed the diagnosis of celiac disease according to Marsh criteria [12] . Therefore, we had to discuss possibly the elevated prevalence of positive htTG antibodies in ASP and PsA patients as a part of an autoimmune overlap syndrome.
There are conXicting data about autoimmune disorders and both htTG antibodies and celiac disease. Kallikorm et al. [13] found an association of seronegative spondylarthropathy with celiac disease in one patient out of 74. Altogether, 74 patients (28 females and 46 males, from 15 to 72 years of age, mean age 40.4 + 1.6 years) with seronegative spondylarthropathy were examined. Of these, 23 patients had reactive arthritis, 12 Reiter's syndrome, 11 PsA, 18 ASP and 10 undiVerentiated spondylarthropathy. From this reason our results may diVer, too. The study of Riente et al. [14] failed to show an increased prevalence of autoantibodies associated with celiac disease in patients with ASP or PsA. The prevalence of previously undiagnosed celiac disease, tested serologically with endomysial antibody, in rheumatoid arthritis is 0 in 160 patients [15] . Given the conXicting results of our study and Riente's and Kallikorm's group, the estimation of htTG antibodies in serum of patients with seronegative spondylarthropathy including ASP or PsA diVered possibly by the used ELISA or other laboratory methods. In Kallikorm's study IgA-type endomysium antibodies were measured by an immunoWxation method, using cryostat sections from human umbilical cord as the antigen substrate [13] . The available ELISA based on the commercial guinea pig tTG antigen may possibly detect antibodies that are nonspeciWc for celiac disease, and hence a test based on pure human tTG may yield increased speciWcity.
What were the clinical consequences of positive htTG antibodies in patients with ASP or PsA? We were able to present both a serological observation and a functional link between positive htTG antibodies and alterations of the vitamin D metabolism. Our ASP patients have been shown expressed both a higher prevalence of positive htTG antibodies and lowered levels of 25 (OH) D3. Compared to recent studies, the prevalence of osteopenia and osteoporosis was highest in newly diagnosed celiac patients and in patients with disease not in remission. A low 25 (OH)D3 vitamin concentration was a typical biochemical abnormality in celiac patients (64% of men and 71% of women) [16] .
Vitamin D metabolites have important functions in regulating inXammatory processes and act on both types of bone cells: osteoblasts and osteoclasts. Furthermore, decreased levels of 1,25 (OH)2 vitamin D3 in ASP patients may induce a reduction in intestinal calcium absorption and periods of disease activity may contribute to a further acceleration of a pre-existing negative calcium balance. Lowered levels of 1,25 (OH)2 Vitamin D3 as an endogenous immune modulator suppressing activated T cells and the proliferation of cells may accelerate the inXammatory process [17] . However, 25 (OH) D3 have been shown to be within normal range in ASP patients in the Lange study [17] . The additional positive htTG antibodies in ASP patients of our study were directly related to lowered 25 (OH) D3. The cohort of PsA patients with a small number of positive htTG antibodies presented markedly elevated levels of 25 (OH) D3. The immune response is more severe expressed in younger ASP patients with additional positive htTG antibodies. However, the younger patients with ASP were well characterized with higher physical activity and longer sun light exposure. Therefore, these patients were able to compensate for lower 25 (OH) D3 and presented 1,25 (OH)2 Vitamin D3 within the normal range.
The major aim of this study was to deWne whether serum measurement of htTG antibodies, which can easily be performed in daily clinical practice, had a diagnostic or predictive value regarding vitamin D metabolism in patients suVering from ASP or PsA. Based on our results, we conclude that the assessment of htTG in ASP may be of interest from a pathophysiological point of view; however, its role in clinical routine as a biochemical marker remains questionable [18] .
